| 2.24 -0.01 (-0.44%) | 04-19 11:44 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.06  |
1-year : | 5.24 |
| Resists | First : | 3.48 |
Second : | 4.48 |
| Pivot price | 2.8 |
|||
| Supports | First : | 1.85 | Second : | 1.53 |
| MAs | MA(5) : | 2.2 |
MA(20) : | 3.01 |
| MA(100) : | 2.28 |
MA(250) : | 1.53 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 21.5 |
D(3) : | 15.4 |
| RSI | RSI(14): 38.1 |
|||
| 52-week | High : | 6.84 | Low : | 0.64 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LEXX ] has closed above bottom band by 23.7%. Bollinger Bands are 60.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.73 - 2.75 | 2.75 - 2.76 |
| Low: | 2.22 - 2.24 | 2.24 - 2.25 |
| Close: | 2.32 - 2.34 | 2.34 - 2.36 |
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Tue, 16 Apr 2024
Lexaria Advances with New GLP-1 Drug Study - TipRanks.com - TipRanks
Tue, 16 Apr 2024
Lexaria gets ethics board okay for oral GLP-1 study (NASDAQ:LEXX) - Seeking Alpha
Thu, 11 Apr 2024
Lexaria Bioscience Second Quarter 2024 Earnings: US$0.06 loss per share (vs US$0.22 loss in 2Q 2023) - Simply Wall St
Tue, 26 Mar 2024
Is Lexaria Bioscience Corp (LEXX) Stock Worth a Buy Tuesday? - InvestorsObserver
Mon, 25 Mar 2024
Is Lexaria Bioscience Corp (LEXX) a Stock to Watch After Gaining 14.12% This Week? - InvestorsObserver
Thu, 14 Mar 2024
Lexaria Bioscience Welcomes New CFO - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 8.5 (%) |
| Held by Institutions | 9 (%) |
| Shares Short | 490 (K) |
| Shares Short P.Month | 668 (K) |
| EPS | -0.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.52 |
| Profit Margin | 0 % |
| Operating Margin | -460.7 % |
| Return on Assets (ttm) | -59.4 % |
| Return on Equity (ttm) | -101.5 % |
| Qtrly Rev. Growth | 624 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -3.36 |
| PEG Ratio | 0 |
| Price to Book value | 4.24 |
| Price to Sales | 71.65 |
| Price to Cash Flow | -5.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|